The ‐A2518G polymorphism in the MCP‐1 gene and inflammatory bowel disease risk: A meta‐analysis. Issue 4 (April 2015)

• Record Type: Journal Article
• Authors: Li, Yu Wen; Yang, Ci Qiu; Xiao, Ying Lian; Li, Jie; Xie, Chen Xi; Zhang, Sheng Hong; Yu, Qiao; Wang, Hui Ling; Lu, Wei Ming; Chen, Min Hu
• Is Part Of: Journal of digestive diseases. Volume 16:Issue 4(2015:Apr.)
• Page Start: 177
• Page End: 185
• Publication Date: 2015-04
• Subjects: Digestive organs -- Diseases -- Periodicals; Gastroenterology -- Periodicals; 616.3
• DOI: 10.1111/1751-2980.12232
• Languages: English
• ISSNs: 1751-2972

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="cdd12232-sec-0001" sec-type="section"> <title>Objective</title> <p>The monocyte chemoattractant protein‐1 (<italic>MCP‐1</italic>) ‐A2518G gene polymorphism has been found to be involved in the susceptibility to inflammatory bowel disease (IBD); however, the results of existing studies are controversial. The aim of this meta‐analysis was to assess the relationship between the <italic>MCP‐1</italic> ‐A2518G polymorphism and the risk of IBD.</p> </sec> <sec id="cdd12232-sec-0002" sec-type="section"> <title>Methods</title> <p>PubMed, EMBASE and MEDLINE were searched for studies assessing the relationship between the ‐A2518G polymorphism in <italic>MCP‐1</italic> gene and the risk of IBD. Available data were extracted and statistically analyzed using STATA 12.0.</p> </sec> <sec id="cdd12232-sec-0003" sec-type="section"> <title>Results</title> <p>A total of five publications involving 3137 individuals (1818 IBD cases and 1319 controls) were included in the meta‐analysis. A combined analysis revealed that the <italic>MCP‐1</italic> ‐A2518G polymorphism in was a protective factor for GG + AG <italic>vs</italic> AA (OR 0.76, 95% CI 0.67–0.87, <italic>P</italic> = 0.000). Subgroup analysis by ethnicity showed that among European patients the AG + GG homozygote, unlike the AA homozygote, had a protective effect against IBD (OR 0.73, 95% CI 0.63–0.84, <italic>P</italic> = 0.000), but did not do so among Asian and African patients. Subgroup analysis by disease subtype suggested the ‐A2518G polymorphism in MCP‐1 had a protective effect against Crohn's disease (OR 0.69, 95% CI 0.58–0.81, <italic>P</italic> = 0.000), but not against ulcerative colitis.</p> </sec> <sec id="cdd12232-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Our meta‐analysis suggested that the ‐A2518G polymorphism in <italic>MCP‐1</italic> may be a protective factor for IBD in European populations. Further studies are required to confirm these findings.</p> </sec> </abstract>